<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30652748</article-id><article-id pub-id-type="pmc">6326448</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0116</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>ACT Values after Neutralization Lower than Pre-heparinization ACT
Leads to Lower Operative Times, Bleeding, and Post-Operative Transfusions in
CABG Patients: an Observational Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Weitie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yongwang</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jinshan</given-names></name><xref ref-type="aff" rid="aff4">4</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Rihao</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Chai</surname><given-names>Junwu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Honglei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Xue</surname><given-names>Fenlong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Kong</surname><given-names>Xiangrong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Kai</surname><given-names>Wang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Cardiovascular Surgery, 1st Central Hospital of
Tianjin, Tianjin, China. </aff><aff id="aff2">
<label>2</label> Department of Cardiovascular Surgery, 2nd Hospital of Bethune,
Jilin University, Changchun, Jilin, China. </aff><aff id="aff3">
<label>3</label> Department of Anesthesiology, 1st Central Hospital of Tianjin,
Tianjin, China. </aff><aff id="aff4">
<label>4</label> Department of Cell Transplantation, 1st Central Hospital of
Tianjin, Tianjin, China. </aff><author-notes><corresp id="c1">Correspondence Address: Wang Kai, 24 Fukang Rd - Nankai Qu, Tianjin
Shi, China, Zip Code: 300000. E-mail:
<email>13920008013@163.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Nov-Dec</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2018</year></pub-date><volume>33</volume><issue>6</issue><fpage>588</fpage><lpage>596</lpage><history><date date-type="received"><day>17</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>11</day><month>6</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To evaluate if lower activated coagulation time (ACT) value after
neutralization than preoperative ACT value was effective in reducing
bleeding, operative times, and post-operative transfusions in patients
underwent coronary artery bypass grafting (CABG).</p></sec><sec><title>Methods</title><p>Retrospective selection of 398 patients from January 2014 to May 2017.
Patients were divided into 2 groups according to final ACT after
neutralization: A - final ACT lower than preoperative ACT; and B - final ACT
higher than or equal to preoperative ACT. Hemostatic time, intraoperative
blood loss, ACT after final neutralization, mediastinal blood loss, and
transfusion requirements were observed.</p></sec><sec><title>Results</title><p>The hourly blood loss in the Group A was generally lower than in the Group B
at first 3 hours, which has significant difference
(<italic>P</italic>&#x0003c;0.05). However, there was no difference after 3 hours
between the two groups. Operative time, intraoperative blood loss,
mediastinal blood loss, transfusion requirements, and drainage in the first
postoperative 12 hours in the Group A were lower than in Group B, which has
significant difference (<italic>P</italic>&#x0003c;0.05).</p></sec><sec><title>Conclusion</title><p>As a result, final ACT values lower than pre-heparinization ACT values are
safe and lead to lower operative times, bleeding, and post-operative
transfusions.</p></sec></abstract><kwd-group><kwd>Cardiopulmonary Bypass</kwd><kwd>Coronary Artery Bypass</kwd><kwd>Thromboelastography</kwd><kwd>Whole Blood Coagulation Time</kwd><kwd>Protamines</kwd></kwd-group></article-meta></front><body><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="19%" span="1"/><col width="79%" span="1"/></colgroup><thead><tr style="background-color:#eaeaea"><th align="left" colspan="2" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>ACT</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Activated coagulation time</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>AKI</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Acute kidney injury</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>CABG</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Coronary artery bypass grafting</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>CPB</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Cardiopulmonary bypass</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>DSWI</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Deep sternal wound infection</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>ECG</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Electrocardiogram</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>HB</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Hemoglobin</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>ICU</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Intensive care unit</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>LMWH</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Low molecular weight heparin</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>PLT</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Platelet</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>TEG</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Thromboelastography</bold></td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Cardiopulmonary bypass (CPB) is a component of cardiac surgeries which requires full
systemic heparinization before it is started<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Protamine is administered to neutralize
the heparin's anticoagulant effect after CPB to return to normal hemostasis.
Activated coagulation time (ACT) has been widely used to monitor the heparin's
intraoperative anticoagulant effect, it needs to exceed 480 seconds before starting
CPB and it is required to be equal to the preoperative value after neutralization.
However, we found less bleeding in some cases whose final ACT after neutralization
was a little lower than pre-heparin ACT. In these cases, the closing time was
shorter than the pre-heparin one. Thereafter, a retrospective observational study
was performed on patients to compare the influence of the final ACT on the outcomes
of cardiac patients.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This is a retrospective observational study conducted from January 2014 to May 2017.
All patients undergoing on-pump coronary artery bypass grafting (CABG) were
enrolled. Exclusion criteria included patients: 1) with liver disease, 2) renal
disease, 3) known bleeding diathesis, 4) who received antiplatelet (aspirin) or
fibrinolytic agents within 5 days before surgery, 5) with platelet (PLT) count &#x0003c;
100*10<sup>9</sup>, 6) abnormal preoperative thromboelastography (TEG)
parameters, 7) preoperative infections, 8) preoperative anemia, and 9) incomplete
clinical records. Finally, 398 patients were enrolled in this study. This study was
approved by the Clinical Trial Ethics Committee of the 1<sup>st</sup> Central
Hospital of Tianjin (Certificate no: E2016023L).</p><p>Patients were divided into 2 groups according to the final ACT after neutralization
before they were transferred to intensive care unit (ICU). Patients whose final ACT
was lower than preoperative ACT were in the Group A and those with final ACT equal
to or higher than preoperative ACT were in the Group B. The following parameters
were collected from our database: gender, height, weight, body surface area, CPB
time, aortic cross-clamp time, minimum temperature reached during CPB, basal ACT,
initial heparin bolus, post-heparinization ACT, ACT levels during CPB, final ACT,
closing time, intraoperative blood loss, the first 12 hours and total bleeding from
the chest drainage, need for transfusion in the ICU, and need for reoperation
resulting from bleeding and other complications.</p><sec><title>Heparin and Protamine Management</title><p>Basal ACT was monitored initially after the patient was transferred to the
operation room and it was used as a reference value after neutralization. At the
same time, another blood sample was collected to determine the baseline
coagulation ability by using heparin-modified TEG.</p><p>Heparin (Tianjin Biochemical Pharmaceutical Co Ltd, Tianjin, China) was given at
an initial dose of 3 mg/kg to achieve an ACT (Medtronic Inc., Minneapolis, MN,
USA) higher than 480 seconds before CPB, which was instituted with an ascending
aortic cannula and a two-stage right atrial cannula in all patients. Moderate
systemic hypothermia (28-30&#x000ba;C) was maintained during CABG. ACT was measured
every 30 minutes during CPB to monitor intraoperative heparin. Additional
heparin bolus (5.000 U) was given if the ACT was &#x0003c; 480 seconds. After
discontinuation of CPB, heparin was reversed with a bolus of protamine sulphate
using the heparin-ACT dose-response curve method to determine the dosage of
protamine. Actually, ACT was measured (30 minutes later) after the first
neutralization. Additional small doses of protamine (10-25 mg) were administered
in patients whose ACT was still higher than the pre-heparin values after the
first neutralization and even if the ACT was between 140-200 according to the
anesthesiologist's experience. Final blood samples were collected for ACT and
TEG assays at the same time. The initial dose plus the additional doses of
protamine are equal to the total dose of protamine in the surgery.</p><p>All residual post-CPB cardiotomy blood was transfused through the venous line
before protamine administration. Cell-saving devices were used in all patients.
Recollected blood and other blood products were transfused if hemoglobin (HB)
was &#x0003c; 80 g/L. ACT was measured by using 2 mL of blood. TEG was carried out by
a TEG Hemostasis Analyzer (Beijing Universal Medical Technology Co Ltd, Beijing,
China); we measured basal ACT, post-heparinization, and final levels in
normothermic conditions. All measurements were done according to the
manufacturer's instructions.</p><p>All surgeries were performed by the same surgeons, anesthesiologists, and
perfusionists. The anesthesiologist is the only one in charge of determining the
dose of protamine.</p></sec><sec><title>Clinical Outcomes</title><p>
<list list-type="bullet"><list-item><p>Surgical mortality: death occurring in hospitalization.</p></list-item><list-item><p>Re-sternotomy for bleeding: reoperation to control bleeding within 36
hours following initial surgery.</p></list-item><list-item><p>Postoperative myocardial infarction: the appearance of new Q waves in
2 or more contiguous leads on the electrocardiogram (ECG).</p></list-item><list-item><p>Atrial/ventricular arrhythmia after surgery: any episode of
atrial/ventricular fibrillation that was registered by the
monitoring system on a rhythm strip or the 12-lead ECG.</p></list-item><list-item><p>Hemostatic time: time between the first protamine injection until
sternal closure.</p></list-item><list-item><p>Postoperative respiratory failure: duration of mechanical ventilation
&#x0003e; 72 hours or re-intubation following surgery.</p></list-item><list-item><p>Postoperative pneumonia: a positive result in a sputum culture
requiring anti-infective treatment or the chest X-ray diagnosis of
pneumonia following cardiac surgery.</p></list-item><list-item><p>Stroke: new permanent neurological event.</p></list-item><list-item><p>Deep sternal wound infection (DSWI): bone related, any drainage of
purulent material from the sternotomy wound and instability of the
sternum.</p></list-item><list-item><p>Acute kidney injury (AKI): defined and classified according to the
criteria proposed by the Acute Kidney Injury Network.</p></list-item><list-item><p>Adverse events of protamine: were caused directly by protamine,
occurred within 30 minutes after the initiation of protamine, and
met one or more of the following criteria - (1) decrease in systemic
arterial blood pressure; (2) increase in pulmonary arterial pressure
of at least 25% resulting in decrease of systemic arterial blood
pressure as defined in (1); (3) non-cardiogenic pulmonary edema; and
(4) bronchospasm.</p></list-item><list-item><p>Heparin rebound: reappearance of hypocoagulability after adequate
neutralization of heparin, which was measured by the increasing ACT
after operation than the final ACT after neutralization in
operation.</p></list-item><list-item><p>Intraoperative blood loss: all the gauzes used for bleeding were
placed on the physical balance and weighed, then the original weight
was subtracted from these gauzes, and the difference was the weight
of blood lost which was converted into milliliters by dividing the
weight by specific gravity, which is 1.055.</p></list-item></list>
</p></sec><sec><title>Statistics</title><p>All statistical analyses were performed using the computer program SPSS 18.0.
Results were expressed as mean&#x000b1;standard deviation. An independent
2-sample Student's t test was employed to analyze continuous data. For the
association between categorical variables, we used X<sup>2</sup>. We considered
a <italic>P</italic> value &#x0003c;0.05 statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>All patients' preoperative characteristics are shown in <xref rid="t1" ref-type="table">Table 1</xref>. Patients' characteristics had no statistical difference
between the two groups.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline and procedural characteristics after matching.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Group A (n=168)</th><th align="center" rowspan="1" colspan="1">Group B (n=230)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years old)</td><td align="center" rowspan="1" colspan="1">54.11&#x000b1;19.16</td><td align="center" rowspan="1" colspan="1">53.97&#x000b1;19.55</td><td align="center" rowspan="1" colspan="1">0.9433</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">81 (48.21%)</td><td align="center" rowspan="1" colspan="1">102 (44.34%)</td><td align="center" rowspan="1" colspan="1">0.4446</td></tr><tr><td align="left" rowspan="1" colspan="1">Obesity (BMI &#x0003e;30 kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">75 (44.64%)</td><td align="center" rowspan="1" colspan="1">89 (38.70%)</td><td align="center" rowspan="1" colspan="1">0.2338</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">91 (54.17%)</td><td align="center" rowspan="1" colspan="1">105 (45.65%)</td><td align="center" rowspan="1" colspan="1">0.0933</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA class III-IV</td><td align="center" rowspan="1" colspan="1">40 (23.81%)</td><td align="center" rowspan="1" colspan="1">52 (22.61%)</td><td align="center" rowspan="1" colspan="1">0.7790</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous myocardial infarction</td><td align="center" rowspan="1" colspan="1">59 (35.12%)</td><td align="center" rowspan="1" colspan="1">67 (29.13%)</td><td align="center" rowspan="1" colspan="1">0.2046</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous PCI</td><td align="center" rowspan="1" colspan="1">48 (28.57%)</td><td align="center" rowspan="1" colspan="1">66 (28.70%)</td><td align="center" rowspan="1" colspan="1">0.9784</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">75 (44.64%)</td><td align="center" rowspan="1" colspan="1">88 (38.26%)</td><td align="center" rowspan="1" colspan="1">0.2010</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">24 (14.29%)</td><td align="center" rowspan="1" colspan="1">34 (14.78%)</td><td align="center" rowspan="1" colspan="1">0.8896</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperlipemia</td><td align="center" rowspan="1" colspan="1">99 (58.93%)</td><td align="center" rowspan="1" colspan="1">110 (47.83%)</td><td align="center" rowspan="1" colspan="1">0.0285</td></tr><tr><td align="left" rowspan="1" colspan="1">COPD</td><td align="center" rowspan="1" colspan="1">18 (10.71%)</td><td align="center" rowspan="1" colspan="1">23 (10.00%)</td><td align="center" rowspan="1" colspan="1">0.8169</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior cerebrovascular accident</td><td align="center" rowspan="1" colspan="1">8 (4.76%)</td><td align="center" rowspan="1" colspan="1">11 (4.78%)</td><td align="center" rowspan="1" colspan="1">0.9924</td></tr><tr><td align="left" rowspan="1" colspan="1">Segmental cardiac wall-motion abnormalities</td><td align="center" rowspan="1" colspan="1">78 (46.43%)</td><td align="center" rowspan="1" colspan="1">84 (36.52%)</td><td align="center" rowspan="1" colspan="1">0.0469</td></tr><tr><td align="left" rowspan="1" colspan="1">Extent of CAD</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Left main stem disease</td><td align="center" rowspan="1" colspan="1">35 (20.83%)</td><td align="center" rowspan="1" colspan="1">43 (18.70%)</td><td align="center" rowspan="1" colspan="1">0.5957</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;3 vessels</td><td align="center" rowspan="1" colspan="1">86 (51.19%)</td><td align="center" rowspan="1" colspan="1">107 (46.52%)</td><td align="center" rowspan="1" colspan="1">0.3573</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;2 vessels</td><td align="center" rowspan="1" colspan="1">70 (41.67%)</td><td align="center" rowspan="1" colspan="1">103 (44.78%)</td><td align="center" rowspan="1" colspan="1">0.5357</td></tr><tr><td align="left" rowspan="1" colspan="1">Logistic EuroSCORE</td><td align="center" rowspan="1" colspan="1">7.6&#x000b1;2.8</td><td align="center" rowspan="1" colspan="1">7.7&#x000b1;2.5</td><td align="center" rowspan="1" colspan="1">0.7082</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><p>BMI=body mass index; CAD=coronary artery disease; COPD=chronic
obstructive pulmonary disease; NYHA=New York Heart Association;
PCI=percutaneous coronary intervention</p></fn></table-wrap-foot></table-wrap><p>All patients' perioperative characteristics are shown in <xref rid="t2" ref-type="table">Table 2</xref>. Patients' liver function, renal function, coagulation
function, and homeostasis had no statistical difference between the two groups.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Preoperative characteristics after matching.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Group A (n=168)</th><th align="center" rowspan="1" colspan="1">Group B (n=230)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1"><bold>Before operation</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">HB (mg/L)</td><td align="center" rowspan="1" colspan="1">121.78&#x000b1;16.79</td><td align="center" rowspan="1" colspan="1">122.13&#x000b1;17.01</td><td align="center" rowspan="1" colspan="1">0.8386</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (umol/L)</td><td align="center" rowspan="1" colspan="1">72.14&#x000b1;11.78</td><td align="center" rowspan="1" colspan="1">72.42&#x000b1;11.98</td><td align="center" rowspan="1" colspan="1">0.8167</td></tr><tr><td align="left" rowspan="1" colspan="1">Glutamic pyruvic transaminase (U/L)</td><td align="center" rowspan="1" colspan="1">35.98&#x000b1;17.24</td><td align="center" rowspan="1" colspan="1">36.04&#x000b1;17.87</td><td align="center" rowspan="1" colspan="1">0.9732</td></tr><tr><td align="left" rowspan="1" colspan="1">Total bilirubin (umol/L)</td><td align="center" rowspan="1" colspan="1">15.42&#x000b1;6.67</td><td align="center" rowspan="1" colspan="1">15.59&#x000b1;6.71</td><td align="center" rowspan="1" colspan="1">0.8025</td></tr><tr><td align="left" rowspan="1" colspan="1">pH (blood gas)</td><td align="center" rowspan="1" colspan="1">7.39&#x000b1;0.08</td><td align="center" rowspan="1" colspan="1">7.40&#x000b1;0.07</td><td align="center" rowspan="1" colspan="1">0.1860</td></tr><tr><td align="left" rowspan="1" colspan="1">Activated partial thromboplastin time (s)</td><td align="center" rowspan="1" colspan="1">11.21&#x000b1;2.45</td><td align="center" rowspan="1" colspan="1">11.20&#x000b1;2.46</td><td align="center" rowspan="1" colspan="1">0.9680</td></tr><tr><td align="left" rowspan="1" colspan="1">INR</td><td align="center" rowspan="1" colspan="1">0.98&#x000b1;0.11</td><td align="center" rowspan="1" colspan="1">0.99&#x000b1;0.10</td><td align="center" rowspan="1" colspan="1">0.3455</td></tr><tr><td align="left" rowspan="1" colspan="1">Partial thrombin time (s)</td><td align="center" rowspan="1" colspan="1">34.78&#x000b1;8.75</td><td align="center" rowspan="1" colspan="1">35.01&#x000b1;8.87</td><td align="center" rowspan="1" colspan="1">0.7973</td></tr><tr><td align="left" rowspan="1" colspan="1">Thrombin time (s)</td><td align="center" rowspan="1" colspan="1">14.87&#x000b1;3.78</td><td align="center" rowspan="1" colspan="1">14.79&#x000b1;3.81</td><td align="center" rowspan="1" colspan="1">0.8357</td></tr><tr><td align="left" rowspan="1" colspan="1">Fibrinogen (g/L)</td><td align="center" rowspan="1" colspan="1">3.74&#x000b1;0.98</td><td align="center" rowspan="1" colspan="1">3.77&#x000b1;1.01</td><td align="center" rowspan="1" colspan="1">0.7671</td></tr><tr><td align="left" rowspan="1" colspan="1">Thromboelastography</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Reaction time to clot initiation (s)</td><td align="center" rowspan="1" colspan="1">3.63&#x000b1;0.77</td><td align="center" rowspan="1" colspan="1">3.67&#x000b1;0.71</td><td align="center" rowspan="1" colspan="1">0.5926</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Clot formation time (s)</td><td align="center" rowspan="1" colspan="1">1.33&#x000b1;0.13</td><td align="center" rowspan="1" colspan="1">1.32&#x000b1;0.12</td><td align="center" rowspan="1" colspan="1">0.4285</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Alpha</td><td align="center" rowspan="1" colspan="1">73.76&#x000b1;6.76</td><td align="center" rowspan="1" colspan="1">74.16&#x000b1;6.53</td><td align="center" rowspan="1" colspan="1">0.5524</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Maximum amplitude</td><td align="center" rowspan="1" colspan="1">65.68&#x000b1;4.44</td><td align="center" rowspan="1" colspan="1">64.98&#x000b1;4.29</td><td align="center" rowspan="1" colspan="1">0.1140</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>After CPB</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">HB (mg/L)</td><td align="center" rowspan="1" colspan="1">100.98&#x000b1;20.17</td><td align="center" rowspan="1" colspan="1">100.76&#x000b1;20.87</td><td align="center" rowspan="1" colspan="1">0.9162</td></tr><tr><td align="left" rowspan="1" colspan="1">pH (blood gas)</td><td align="center" rowspan="1" colspan="1">7.44&#x000b1;0.08</td><td align="center" rowspan="1" colspan="1">7.43&#x000b1;0.07</td><td align="center" rowspan="1" colspan="1">0.1860</td></tr><tr><td align="left" rowspan="1" colspan="1">Activated partial thromboplastin time (s)</td><td align="center" rowspan="1" colspan="1">11.54&#x000b1;2.75</td><td align="center" rowspan="1" colspan="1">11.51&#x000b1;2.71</td><td align="center" rowspan="1" colspan="1">0.9137</td></tr><tr><td align="left" rowspan="1" colspan="1">INR</td><td align="center" rowspan="1" colspan="1">0.99&#x000b1;0.22</td><td align="center" rowspan="1" colspan="1">0.98&#x000b1;0.37</td><td align="center" rowspan="1" colspan="1">0.7550</td></tr><tr><td align="left" rowspan="1" colspan="1">Partial thrombin time (s)</td><td align="center" rowspan="1" colspan="1">34.70&#x000b1;8.95</td><td align="center" rowspan="1" colspan="1">34.71&#x000b1;8.55</td><td align="center" rowspan="1" colspan="1">0.9910</td></tr><tr><td align="left" rowspan="1" colspan="1">Thrombin time (s)</td><td align="center" rowspan="1" colspan="1">14.89&#x000b1;3.57</td><td align="center" rowspan="1" colspan="1">14.88&#x000b1;3.67</td><td align="center" rowspan="1" colspan="1">0.9783</td></tr><tr><td align="left" rowspan="1" colspan="1">Fibrinogen (g/L)</td><td align="center" rowspan="1" colspan="1">3.73&#x000b1;0.87</td><td align="center" rowspan="1" colspan="1">3.74&#x000b1;0.89</td><td align="center" rowspan="1" colspan="1">0.9111</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (umol/L)</td><td align="center" rowspan="1" colspan="1">72.34&#x000b1;12.07</td><td align="center" rowspan="1" colspan="1">72.79&#x000b1;11.98</td><td align="center" rowspan="1" colspan="1">0.7124</td></tr><tr><td align="left" rowspan="1" colspan="1">Glutamic pyruvic transaminase (umol/L)</td><td align="center" rowspan="1" colspan="1">35.71&#x000b1;16.74</td><td align="center" rowspan="1" colspan="1">36.14&#x000b1;16.82</td><td align="center" rowspan="1" colspan="1">0.8009</td></tr><tr><td align="left" rowspan="1" colspan="1">Total bilirubin (umol/L)</td><td align="center" rowspan="1" colspan="1">16.71&#x000b1;6.21</td><td align="center" rowspan="1" colspan="1">16.99&#x000b1;7.01</td><td align="center" rowspan="1" colspan="1">0.6800</td></tr><tr><td align="left" rowspan="1" colspan="1">Thromboelastography</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Reaction time to clot initiation (s)</td><td align="center" rowspan="1" colspan="1">3.59&#x000b1;0.53</td><td align="center" rowspan="1" colspan="1">3.66&#x000b1;0.69</td><td align="center" rowspan="1" colspan="1">0.2724</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Clot formation time (s)</td><td align="center" rowspan="1" colspan="1">1.29&#x000b1;0.18</td><td align="center" rowspan="1" colspan="1">1.31&#x000b1;0.12</td><td align="center" rowspan="1" colspan="1">0.1847</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Alpha</td><td align="center" rowspan="1" colspan="1">73.90&#x000b1;6.59</td><td align="center" rowspan="1" colspan="1">74.10&#x000b1;6.66</td><td align="center" rowspan="1" colspan="1">0.7665</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Maximum amplitude</td><td align="center" rowspan="1" colspan="1">72.12&#x000b1;6.33</td><td align="center" rowspan="1" colspan="1">72.32&#x000b1;6.43</td><td align="center" rowspan="1" colspan="1">0.7579</td></tr></tbody></table><table-wrap-foot><fn id="TFN02"><p>CPB=cardiopulmonary bypass; HB=hemoglobin; INR=international normalized
ratio</p></fn></table-wrap-foot></table-wrap><sec><title>Intraoperative Outcomes</title><p>Intraoperative data are shown in <xref rid="t3" ref-type="table">Table 3</xref>.
There was no statistical difference between the two groups including
preoperative ACT, CPB time, cross-clamp time, number of distal anastomosis, ACT
after CPB, cases who need additional protamine, and the additional quantity of
protamine (<italic>P</italic>&#x0003e;0.05). However, the last ACT in the operation
room, hemostatic time, intraoperative blood loss, and erythrocyte suspension
presented statistical difference between the two groups
(<italic>P</italic>&#x0003c;0.05).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Intraoperative data.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Group A (n=168)</th><th align="center" rowspan="1" colspan="1">Group B (n=230)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Preoperative ACT</td><td align="center" rowspan="1" colspan="1">209.22&#x000b1;19.91</td><td align="center" rowspan="1" colspan="1">209.19&#x000b1;20.02</td><td align="center" rowspan="1" colspan="1">0.9882</td></tr><tr><td align="left" rowspan="1" colspan="1">Time of CPB (min)</td><td align="center" rowspan="1" colspan="1">39.23&#x000b1;5.21</td><td align="center" rowspan="1" colspan="1">39.91&#x000b1;5.13</td><td align="center" rowspan="1" colspan="1">0.1952</td></tr><tr><td align="left" rowspan="1" colspan="1">Cross-clamp time (min)</td><td align="center" rowspan="1" colspan="1">34.12&#x000b1;11.56</td><td align="center" rowspan="1" colspan="1">34.20&#x000b1;11.73</td><td align="center" rowspan="1" colspan="1">0.9461</td></tr><tr><td align="left" rowspan="1" colspan="1">Temperature during CPB (&#x000ba;C)</td><td align="center" rowspan="1" colspan="1">28-30</td><td align="center" rowspan="1" colspan="1">28-30</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">No. distal anastomosis</td><td align="center" rowspan="1" colspan="1">2.46&#x000b1;0.82</td><td align="center" rowspan="1" colspan="1">2.50&#x000b1;0.81</td><td align="center" rowspan="1" colspan="1">0.6286</td></tr><tr><td align="left" rowspan="1" colspan="1">ACT after CPB</td><td align="center" rowspan="1" colspan="1">475.27&#x000b1;21.11</td><td align="center" rowspan="1" colspan="1">477.19&#x000b1;21.20</td><td align="center" rowspan="1" colspan="1">0.3719</td></tr><tr><td align="left" rowspan="1" colspan="1">Cases needing additional protamine</td><td align="center" rowspan="1" colspan="1">117 (69.43)</td><td align="center" rowspan="1" colspan="1">159 (69.13)</td><td align="center" rowspan="1" colspan="1">0.9128</td></tr><tr><td align="left" rowspan="1" colspan="1">Additional protamine (mg)</td><td align="center" rowspan="1" colspan="1">20.76&#x000b1;4.98</td><td align="center" rowspan="1" colspan="1">20.34&#x000b1;5.01</td><td align="center" rowspan="1" colspan="1">0.4081</td></tr><tr><td align="left" rowspan="1" colspan="1">Last ACT in operation room</td><td align="center" rowspan="1" colspan="1">182.77&#x000b1;11.42</td><td align="center" rowspan="1" colspan="1">215.34&#x000b1;14.38</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN04">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Hemostatic time (min)</td><td align="center" rowspan="1" colspan="1">34.19&#x000b1;15.43</td><td align="center" rowspan="1" colspan="1">49.21&#x000b1;21.84</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN04">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Intraoperative blood loss (ml)</td><td align="center" rowspan="1" colspan="1">635.45&#x000b1;67.52</td><td align="center" rowspan="1" colspan="1">863.79&#x000b1;110.72</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN04">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Erythrocyte suspension (U)</td><td align="center" rowspan="1" colspan="1">0.54&#x000b1;0.35</td><td align="center" rowspan="1" colspan="1">1.21&#x000b1;0.55</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN04">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Temperature in operation room (&#x000ba;C)</td><td align="center" rowspan="1" colspan="1">21-24</td><td align="center" rowspan="1" colspan="1">21-24</td><td align="center" rowspan="1" colspan="1">__</td></tr></tbody></table><table-wrap-foot><fn id="TFN03"><p>ACT=activated coagulation time; CPB=cardiopulmonary bypass</p></fn><fn id="TFN04"><label>*</label><p>=<italic>P</italic>&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap><p>The ACT in the first ICU hour presented statistical difference between the two
groups (<italic>P</italic>&#x0003e;0.05). Despite neutralizing the ACT to baseline
level after surgery, there was a reappearance of anticoagulant activity
indicative of heparin rebound as demonstrated by ACT higher than the previous.
So, the number of patients requiring small amounts of protamine to control
excessive bleeding was higher in the Group B, which has statistical significance
(<italic>P</italic>&#x0003e;0.05). Most patients received a small dose (25 mg) of
protamine. Blood in tube in the first 12 hours, blood transfusion in ICU, and
reinfused blood from cell-saving devices in the first 12 hours also presented
statistical significance in the two groups (<italic>P</italic>&#x0003e;0.05) (<xref rid="t4" ref-type="table">Table 4</xref>).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Postoperative data in ICU.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Group A (n=168)</th><th align="center" rowspan="1" colspan="1">Group B (n=230)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ACT in the first ICU hour</td><td align="center" rowspan="1" colspan="1">198.23&#x000b1;9.38</td><td align="center" rowspan="1" colspan="1">230.13&#x000b1;10.21</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN06">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Temperature in ICU (&#x000ba;C)</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Heparin rebound</td><td align="center" rowspan="1" colspan="1">126 (75%)</td><td align="center" rowspan="1" colspan="1">171 (74.5%)</td><td align="center" rowspan="1" colspan="1">0.8826</td></tr><tr><td align="left" rowspan="1" colspan="1">Additional protamine (mg)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">10.33&#x000b1;12.34</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="TFN06">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events of protamine</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Bleed in tube in first 12 hours (ml)</td><td align="center" rowspan="1" colspan="1">159.34&#x000b1;20.32</td><td align="center" rowspan="1" colspan="1">203.32&#x000b1;23.14</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN06">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Blood transfusion in ICU (U)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">0.83&#x000b1;0.99</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN06">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Reinfused blood from cell-saving devices in
first<break/>12 hours (ml)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">143.43&#x000b1;23.33</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="table-fn" rid="TFN06">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN05"><p>ACT=activated coagulation time; ICU=intensive care unit</p></fn><fn id="TFN06"><label>*</label><p>= <italic>P</italic>&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Postoperative Outcomes</title><p>Postoperative outcomes are shown in <xref rid="t5" ref-type="table">Table
5</xref>. No important differences were detected in rate of reoperation,
myocardial infarction, or mortality between the two groups.</p><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Postoperative outcomes.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Group A (n=168)</th><th align="center" rowspan="1" colspan="1">Group B (n=230)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Surgical mortality</td><td align="center" rowspan="1" colspan="1">1 (0.60%)</td><td align="center" rowspan="1" colspan="1">1 (0.43%)</td><td align="center" rowspan="1" colspan="1">0.8231</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative cardiac dysfunction</td><td align="center" rowspan="1" colspan="1">1 (0.60%)</td><td align="center" rowspan="1" colspan="1">1 (0.43%)</td><td align="center" rowspan="1" colspan="1">0.8231</td></tr><tr><td align="left" rowspan="1" colspan="1">Re-sternotomy for bleeding</td><td align="center" rowspan="1" colspan="1">1 (0.60%)</td><td align="center" rowspan="1" colspan="1">1 (0.43%)</td><td align="center" rowspan="1" colspan="1">0.8231</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU stay (day)</td><td align="center" rowspan="1" colspan="1">2.98&#x000b1;0.95</td><td align="center" rowspan="1" colspan="1">3.12&#x000b1;1.14</td><td align="center" rowspan="1" colspan="1">0.1956</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital stay (day)</td><td align="center" rowspan="1" colspan="1">9.92&#x000b1;1.52</td><td align="center" rowspan="1" colspan="1">10.12&#x000b1;1.41</td><td align="center" rowspan="1" colspan="1">0.1771</td></tr><tr><td align="left" rowspan="1" colspan="1">Ventricular arrhythmia</td><td align="center" rowspan="1" colspan="1">2 (1.19%)</td><td align="center" rowspan="1" colspan="1">3 (1.30%)</td><td align="center" rowspan="1" colspan="1">0.9198</td></tr><tr><td align="left" rowspan="1" colspan="1">Low output syndrome</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1 (0.43%)</td><td align="center" rowspan="1" colspan="1">0.3944</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke</td><td align="center" rowspan="1" colspan="1">1 (0.60%)</td><td align="center" rowspan="1" colspan="1">1 (0.43%)</td><td align="center" rowspan="1" colspan="1">0.8231</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarction</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">68 (40.48%)</td><td align="center" rowspan="1" colspan="1">98 (42.61%)</td><td align="center" rowspan="1" colspan="1">0.6700</td></tr><tr><td align="left" rowspan="1" colspan="1">IABP support</td><td align="center" rowspan="1" colspan="1">3 (1.79%)</td><td align="center" rowspan="1" colspan="1">4 (1.74%)</td><td align="center" rowspan="1" colspan="1">0.9721</td></tr><tr><td align="left" rowspan="1" colspan="1">AKI requiring dialysis</td><td align="center" rowspan="1" colspan="1">1 (0.60%)</td><td align="center" rowspan="1" colspan="1">1 (0.43%)</td><td align="center" rowspan="1" colspan="1">0.8231</td></tr><tr><td align="left" rowspan="1" colspan="1">Respiratory failure</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Pneumonia</td><td align="center" rowspan="1" colspan="1">2 (1.19%)</td><td align="center" rowspan="1" colspan="1">3 (1.30%)</td><td align="center" rowspan="1" colspan="1">0.9251</td></tr><tr><td align="left" rowspan="1" colspan="1">DSWI</td><td align="center" rowspan="1" colspan="1">2 (1.19%)</td><td align="center" rowspan="1" colspan="1">3 (1.30%)</td><td align="center" rowspan="1" colspan="1">0.9251</td></tr></tbody></table><table-wrap-foot><fn id="TFN07"><p>AKI=acute kidney injury; DSWI=deep sternal wound infection;
IABP=intra-aortic balloon pump; ICU=intensive care unit</p></fn></table-wrap-foot></table-wrap></sec><sec><title>ACT Continuous Change</title><p>ACT continuous monitoring is shown in <xref ref-type="fig" rid="f1">Figure
1</xref>. There is no difference until the last neutralization.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Activated coagulation time (ACT) continuous monitoring.</p><p>CPB=cardiopulmonary bypass; HTK=histidine-tryptophan-ketoglutarate;
ICU=intensive care unit</p></caption><graphic xlink:href="rbccv-33-06-0588-g01"/></fig>
</p></sec><sec><title>Blood Loss</title><p>The lower ACT has an effect on reducing mediastinal blood loss. As shown in <xref ref-type="fig" rid="f2">Figure 2</xref>, the hourly blood loss in the low
ACT group was generally lower than in the Group B in the first 3 hours, which
has significant difference (<italic>P</italic>&#x0003c;0.05). However, there was no
difference after 3 hours between the two groups.</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>The lower activated coagulation time (ACT) has an effect on reducing
mediastinal blood loss.</p><p>ICU=intensive care unit</p></caption><graphic xlink:href="rbccv-33-06-0588-g02"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Protamine has been routinely administered after CPB in order to neutralize the
effects of heparin for a long time. The dose of protamine used for neutralization
was verified by the ACT value, which must be within normal parameters (100-140
seconds) or at the basal pre-heparin value observed in any case. Many studies aimed
to evaluate the dose of protamine for neutralization<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>]</sup> which can contribute to
coagulopathy if there is an excess<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup> or deficit. However, the protamine dose for
neutralizing the heparin effects was influenced by multiple factors, such as
hypothermia, hemodilution, homeostasis, and so on<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>]</sup>; because of that, a
dosage cannot be determined, so most centers used a dose of protamine equal to 1 or
1.5 times the initial dose of heparin and the final ACT was returned to the basal
value or a little higher than the pre-heparin value.</p><p>However, we found out that after administering protamine (1:1 heparin) and adding
additional protamine according to the ACT value after the first neutralization, some
cases presented ACT values a little lower than pre-heparin ACT before transfer to
ICU. According to the anesthesiologists' experience, because of ACT value is always
higher than pre-heparin ACT after first neutralization, 10-25 mg of additional
protamine would be administered. So, after 20-30 minutes, the ACT value would be
lower than pre-heparin ACT in some cases. Still, the closing time was quicker than
of patients with final ACT longer or equal than pre-heparin ACT. In addition, after
transfer to ICU, the pericardial and mediastinal drainage in the first 12 hours was
also decreasing. So, we retrospectively analyzed cases with final ACT a little lower
than pre-heparin ACT and their closing time, bleeding of first 12 hours, and
perioperative complications and then compared these situations with cases whose
final ACT was longer than or equal to pre-heparin ACT. In our study, we aimed to
evaluate the final ACT after the last neutralization, so we can skip many
interference factors, such as internal environmental disorder and fluctuation of
temperature on coagulation.</p><p>In recent years, TEG<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> has become available to measure several aspects
related to coagulation. It can show several coagulation aspects, such as blood
heparin levels, parameters, and the shortage of PLT. We used TEG to evaluate the PLT
function and fibrinolysis situation after neutralization, which was influenced by
heparin, protamine<sup>[<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r9" ref-type="bibr">9</xref>]</sup>, CPB, and other factors, to exclude the influence of
coagulation on bleeding and closing time. In addition, we monitored other
parameters, like temperature and blood gas, before measuring the last ACT to exclude
other factors that could influence on the closing time and postoperative bleeding.
There were no significant differences between the two groups. Also, heparin rebound,
hyperfibrinolysis, and an acquired PLT defect were considered to be the main
contributors to postoperative bleeding.</p><p>Heparin rebound<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> has been identified in many studies. This occurs
because a proportion of heparin remains nonspecifically bound to plasma proteins and
vascular cells, which can not be cleared by protamine, and that dissociates over
time to produce an anticoagulant effect. The incidence of heparin rebound varies
widely in the literature and it has been reported to be as high as
50%<sup>[<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref>]</sup>. Our study showed that incomplete heparin reversal
and heparin rebound were a very common phenomenon after CPB, occurring in 75% of
patients in Group A and 74.5% of patients in Group B. Heparin rebound would cause
ACT rising directly, and according to this rising ACT, an additional small dose of
protamine (25 mg) was used in Group B; but no protamine was used in Group A because
the rising ACT was at the same level as the pre-heparin ACT. Although the different
side effects of the administration of an additional small dose of protamine, such as
anaphylactic reaction, hypotension, and pulmonary hypertension, were not found in
Group B, in the Group A, these sides effects were avoided by low ACT before
returning to ICU which was safer than the Group B.</p><p>Cardiopulmonary surgery is an inflammatory condition that can stimulate the synthesis
of acute phase proteins that could contribute to increased protein binding. In
addition, prolonged blood contact with the artificial surface of CPB will also
affect PLT function which influences on the postoperative bleeding. Surgical trauma,
high doses of heparin, and hypothermia all induce the activation of the
inflammatory, coagulation, and fibrinolytic systems and the PLT dysfunction, leading
to postoperative coagulopathy. After comparing all TEG parameters, preoperatively
and after the last neutralization, no significant difference was found between the
two groups and the PLT function was normal, probably due to the short CPB time. The
PLT count is normal in both groups with no significant difference on the routine
blood test.</p><p>The authors evaluated closing time, postoperative bleeding, and need for blood
product transfusions. The time of operation was shorter in the Group A due to the
quickly closing time than in the Group B. The hourly blood loss reduction between
the 2 groups was modest (15-30 mL per hour on average), but there was a significant
difference in the first 3 postoperative hours. There was no difference after 4
hours, because of the additional protamine in the Group B after the finding of more
drainage. We just analyzed the first 12 hours drainage because after this period,
drugs would be administered to some of the patients, which would interfere on
coagulation factors. There were more blood product transfusions in the Group B than
in Group A because of more drainage.</p><p>So, why Group A patients with lower final ACT than pre-heparin ACT had positive
effect on reducing closing time and postoperative bleeding? Firstly, ACT of all
patients was longer than normal preoperative ACT because low molecular weight
heparin (LMWH) as anticoagulant was administered 2 times a day until the operation
day. The ACT of all patients was longer than normal and always up to 200-220 before
operation. Thus, even with neutralization lower than pre-heparin, the final ACT in
Group A before leaving the operation room was also longer than normal. The reversion
of the heparin effects after CPB referring to abnormal preoperative ACT was not
useful for these patients in need of anticoagulation preoperative therapy. If the
protamine has neutralized all heparin in the blood, the additional protamine was
used to neutralize LMWH (60%), which made the ACT lower than the preoperative ACT.
Secondly, heparin rebound was found in almost all patients, which would cause ACT
longer after transfer to ICU. So, in Group A, the final ACT was lower than
pre-heparin ACT after neutralization and remained equal or a little higher than
pre-heparin ACT after heparin rebound, which did not require the use of additional
protamine to neutralize it. But, in the Group B, ACT rose much higher than
preoperative ACT after heparin rebound, so additional protamine had to be used for
neutralizing it to prevent bleeding.</p><p>Some people may say that the final ACT lower than the pre-heparin ACT after
neutralization may suggest the excessive use of protamine. It is also well
documented that the excessive protamine leads to prolonged ACT, weakened clot
structure, altered clot kinetics, and PLT dysfunction with subsequent anticoagulant
action<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>, especially if more than 1.3 mg of protamine, per
each milligram of heparin, is administrated. So, we used TEG to evaluate the
fibrinolytic systems and PLT dysfunction between the two groups after the final
neutralization and there were no differences in all TEG parameters.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In summary, we have demonstrated that lower final ACT after neutralization is safe
and has the advantage of leading to lower operative times, bleeding, and
post-operative transfusions.</p><sec><title>Limitation</title><p>This study has several limitations. Firstly, it is a retrospective,
observational, single-centre study, which may influence on the generalizability.
So, a final determination would need a prospective, multi-centre study with
larger sample size. Secondly, ACT does not correlate with true heparin levels,
so it is not accurate to infer the rising ACT caused by heparin rebound.
Thirdly, some patients got fever after operation, which will influence on the
coagulation system. Finally, we do not know the effect of LMWH on final ACT,
because we did not monitor the plasma concentration of LMWH, which remained in
the blood and it was not cleared.</p><table-wrap id="t7" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1"><bold>Authors&#x02019; roles &#x00026;
responsibilities</bold></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">WW</td><td align="center" rowspan="1" colspan="1">Conception and design of the work; acquisition of
data; analysis and interpretation of data; drafting the paper;
revising the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">YW</td><td align="center" rowspan="1" colspan="1">Conception and design of the work; acquisition of
data; analysis and interpretation of data; drafting the paper;
revising the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">JW</td><td align="center" rowspan="1" colspan="1">Conception and design of the work; acquisition of
data; analysis and interpretation of data; drafting the paper;
revising the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">RX</td><td align="center" rowspan="1" colspan="1">Conception and design of the work; acquisition of
data; analysis and interpretation of data; drafting the paper;
revising the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">JC</td><td align="center" rowspan="1" colspan="1">Conception and design of the work; acquisition of
data; analysis and interpretation of data; drafting the paper;
revising the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">WZ</td><td align="center" rowspan="1" colspan="1">Conception and design of the work; acquisition of
data; analysis and interpretation of data; drafting the paper;
revising the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">HC</td><td align="center" rowspan="1" colspan="1">Conception and design of the work; acquisition of
data; analysis and interpretation of data; drafting the paper;
revising the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">FX</td><td align="center" rowspan="1" colspan="1">Conception and design of the work; acquisition of
data; analysis and interpretation of data; drafting the paper;
revising the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">XK</td><td align="center" rowspan="1" colspan="1">Conception and design of the work; acquisition of
data; analysis and interpretation of data; drafting the paper;
revising the work; approval of the final version</td></tr><tr><td align="left" rowspan="1" colspan="1">XK</td><td align="center" rowspan="1" colspan="1">Conception and design of the work; acquisition of
data; analysis and interpretation of data; drafting the paper;
revising the work; approval of the final version</td></tr></tbody></table></table-wrap></sec></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the 1<sup>st</sup> Central Hospital of Tianjin,
Tianjin, China.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ack><title>ACKNOWLEDGEMENT</title><p>We acknowledge the support by Tianjin Medical University under the funding program
Open Access Publishing.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Despotis</surname><given-names>GJ</given-names></name><name><surname>Gravlee</surname><given-names>G</given-names></name><name><surname>Filos</surname><given-names>K</given-names></name><name><surname>Levy</surname><given-names>J</given-names></name></person-group><article-title>Anticoagulation monitoring during cardiac surgery: a review of
current and emerging techniques</article-title><source>Anesthesiology</source><year>1999</year><volume>91</volume><issue>4</issue><fpage>1122</fpage><lpage>1151</lpage><pub-id pub-id-type="pmid">10519514</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamath</surname><given-names>BS</given-names></name><name><surname>Fozard</surname><given-names>JR</given-names></name></person-group><article-title>Control of heparinisation during cardiopulmonary bypass.
Experience with the activated clotting time method</article-title><source>Anaesthesia</source><year>1980</year><volume>35</volume><issue>3</issue><fpage>250</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">7396136</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akl</surname><given-names>BF</given-names></name><name><surname>Vargas</surname><given-names>GM</given-names></name><name><surname>Neal</surname><given-names>J</given-names></name><name><surname>Robillard</surname><given-names>J</given-names></name><name><surname>Kelly</surname><given-names>P</given-names></name></person-group><article-title>Clinical experience with the activated clotting time for the
control of heparin and protamine therapy during cardiopulmonary
bypass</article-title><source>J Thorac Cardiovasc Surg</source><year>1980</year><volume>79</volume><issue>1</issue><fpage>97</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">7350393</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teoh</surname><given-names>KH</given-names></name><name><surname>Young</surname><given-names>E</given-names></name><name><surname>Blackall</surname><given-names>MH</given-names></name><name><surname>Roberts</surname><given-names>RS</given-names></name><name><surname>Hirsh</surname><given-names>J</given-names></name></person-group><article-title>Can extra protamine eliminate heparin rebound following
cardiopulmonary bypass surgery</article-title><source>J Thorac Cardiovasc Surg</source><year>2004</year><volume>128</volume><issue>2</issue><fpage>211</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">15282457</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paparella</surname><given-names>D</given-names></name><name><surname>Brister</surname><given-names>SJ</given-names></name><name><surname>Buchanan</surname><given-names>MR</given-names></name></person-group><article-title>Coagulation disorders of cardiopulmonary bypass: a
review</article-title><source>Intensive Care Med</source><year>2004</year><volume>30</volume><issue>10</issue><fpage>1873</fpage><lpage>1881</lpage><pub-id pub-id-type="pmid">15278267</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>RA</given-names></name><name><surname>Culliford</surname><given-names>AT</given-names></name><name><surname>Colvin</surname><given-names>SB</given-names></name><name><surname>Thomas</surname><given-names>SJ</given-names></name><name><surname>Lackner</surname><given-names>H</given-names></name><name><surname>Spencer</surname><given-names>FC</given-names></name></person-group><article-title>The role of the activated clotting time in heparin administration
and neutralization for cardiopulmonary bypass</article-title><source>J Thorac Cardiovasc Surg</source><year>1983</year><volume>85</volume><issue>2</issue><fpage>174</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">6823136</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallett</surname><given-names>SV</given-names></name><name><surname>Cox</surname><given-names>DJ</given-names></name></person-group><article-title>Thromboelastography</article-title><source>Br J Anaesth</source><year>1992</year><volume>69</volume><issue>3</issue><fpage>307</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">1389849</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>VG</given-names></name></person-group><article-title>Protamine enhances fibrinolysis by decreasing clot strength: role
of tissue factor-initiated thrombin generation</article-title><source>Ann Thorac Surg</source><year>2006</year><volume>81</volume><issue>5</issue><fpage>1720</fpage><lpage>1727</lpage><pub-id pub-id-type="pmid">16631662</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mochizuki</surname><given-names>T</given-names></name><name><surname>Olson</surname><given-names>PJ</given-names></name><name><surname>Szlam</surname><given-names>F</given-names></name><name><surname>Ramsay</surname><given-names>JG</given-names></name><name><surname>Levy</surname><given-names>JH</given-names></name></person-group><article-title>Protamine reversal of heparin affects platelet aggregation and
activated clotting time after cardiopulmonary bypass</article-title><source>Anesth Analg</source><year>1998</year><volume>87</volume><issue>4</issue><fpage>781</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">9768770</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyun</surname><given-names>BH</given-names></name><name><surname>Pence</surname><given-names>RE</given-names></name><name><surname>Davila</surname><given-names>JC</given-names></name><name><surname>Butcher</surname><given-names>J</given-names></name><name><surname>Custer</surname><given-names>RP</given-names></name></person-group><article-title>Heparin rebound phenomenon in extracorporeal
circulation</article-title><source>Surg Gynecol Obstet</source><year>1962</year><volume>115</volume><fpage>191</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">14450355</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pifarre</surname><given-names>R</given-names></name><name><surname>Sullivan</surname><given-names>HJ</given-names></name><name><surname>Montoya</surname><given-names>A</given-names></name><name><surname>Bakhos</surname><given-names>M</given-names></name><name><surname>Grieco</surname><given-names>J</given-names></name><name><surname>Foy</surname><given-names>BK</given-names></name><etal/></person-group><article-title>Management of blood loss and heparin rebound following
cardiopulmonary bypass</article-title><source>Semin Thromb Hemost</source><year>1989</year><volume>15</volume><issue>2</issue><fpage>173</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">2787532</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galeone</surname><given-names>A</given-names></name><name><surname>Rotunno</surname><given-names>C</given-names></name><name><surname>Guida</surname><given-names>P</given-names></name><name><surname>Bisceglie</surname><given-names>A</given-names></name><name><surname>Rubino</surname><given-names>G</given-names></name><name><surname>Schinosa</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Monitoring incomplete heparin reversal and heparin rebound after
cardiac surgery</article-title><source>J Cardiothorac Vasc Anesth</source><year>2013</year><volume>27</volume><issue>5</issue><fpage>853</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">23627997</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slaughter</surname><given-names>TF</given-names></name><name><surname>LeBleu</surname><given-names>TH</given-names></name><name><surname>Douglas Jr</surname><given-names>JM</given-names></name><name><surname>Leslie</surname><given-names>JB</given-names></name><name><surname>Parker</surname><given-names>JK</given-names></name><name><surname>Greenberg</surname><given-names>CS</given-names></name></person-group><article-title>Characterization of prothrombin activation during cardiac surgery
by hemostatic molecular markers</article-title><source>Anesthesiology</source><year>1994</year><volume>80</volume><issue>3</issue><fpage>520</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">8141448</pub-id></element-citation></ref></ref-list></back></article>